Acousia Therapeutics GmbH announces positive top-line first-in-patient results from its completed Phase 2a PROHEAR study evaluating ACOU085 (INN: bimokalner) for cisplatin-induced ototoxicity. The announcement describes ACOU085 as an investigational treatment aimed at protecting or improving hearing outcomes in patients who develop inner-ear damage as a result of cisplatin chemotherapy. Acousia states that the study has reached completion and that early efficacy findings from the first-in-patient cohort are promising. The company also frames the work within its broader clinical-stage program focused on acute and chronic inner ear hearing loss.
The released information is limited to top-line results and does not provide detailed statistical measures or full datasets in the excerpt available from the source. No comparison to a control arm, specific magnitude of effect, safety outcomes, or follow-up plans are included in the provided material.
